News

Apitope’s peptide to take on Haemophilia A


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Apitope’s peptide to take on Haemophilia A

 

Date: 10/06/2015


Apitope’s pre-clinical candidate ATX-F8-117 has been granted Orphan Drug Status by the US FDA for the treatment of Haemophilia A. The drug candidate already obtained an Orphan Drug Designation by the European Medical Agency last year. The compound also awakened the interest of Abzena, which works with Apitope to design the candidate.

Haemophilia A is a rare chronic bleeding disorder which leads to inadequate clotting of the blood in response to any type of injury or surgery. The mainstay of this disease’s treatment is the life-long replacement therapy with synthetic blood-clotting factor (FVIII) in order to achieve haemostasis, using either plasma derived or recombinant FVIII products.

The most challenging complication of the therapy resides in the capacity of patients’ immune systems to develop anti-FVIII neutralising antibodies. These antibodies block the pro-coagulant function of FVIII and are therefore termed inhibitors. The development of such inhibitors sharply decreases the efficacy of the FVIII treatment, which can have severe consequences, including joint damage, brain damage and, ultimately, death. There are currently no treatments available to prevent or treat the development of neutralizing antibodies.

For more click here

Source: Labiotech

© Catalyst Innovation Portal 2019